📊 ANTX Key Takeaways
Is AN2 Therapeutics, Inc. (ANTX) a Good Investment?
AN2 Therapeutics is a pre-revenue biopharmaceutical company burning substantial cash with negative operating cash flow of -$29.8M and minimal runway given $19.9M in cash reserves. The company is unprofitable with no revenue generation, negative ROE of -66.3%, and deteriorating financial health despite maintaining a strong balance sheet relative to liabilities.
AN2 Therapeutics remains a pre-revenue biotechnology company with no commercial income and substantial recurring losses, which makes the fundamental profile highly dependent on cash consumption rather than operating performance. The balance sheet is currently clean, with strong liquidity and no long-term debt, but negative operating cash flow of nearly $30M against roughly $20M of cash suggests funding risk unless spending falls materially or new capital is raised. Profitability trends are still weak despite EPS improvement, because the business has not yet demonstrated revenue generation or self-sustaining growth quality.
Why Buy AN2 Therapeutics, Inc. Stock? ANTX Key Strengths
- Excellent liquidity position with current ratio of 6.87x and $19.9M cash reserves
- No long-term debt burden with debt/equity ratio of 0.00x, reducing financial risk
- Relatively strong stockholders' equity of $53.1M providing balance sheet cushion
- Significant insider activity with 21 Form 4 filings suggesting management engagement
- Strong short-term liquidity with a 6.87x current and quick ratio
- Debt-free capital structure reduces financial leverage risk
- Equity base remains positive at $53.06M, providing some balance sheet cushion
ANTX Stock Risks: AN2 Therapeutics, Inc. Investment Risks
- Pre-revenue stage with zero commercial product income and N/A gross margins indicating no commercialization
- Severe negative cash burn of -$29.8M annually with only ~8 months of cash runway at current burn rate
- Ongoing operating losses of -$38.1M with negative ROE (-66.3%) and ROA (-56.8%), destroying shareholder value
- Clinical/development stage company faces binary outcomes; no evidence of regulatory approval or revenue inflection
- Diluted EPS of -$1.16 reflects heavy shareholder dilution from equity financing to fund ongoing losses
- No revenue base, making the company entirely reliant on external financing and pipeline execution
- Large net loss and negative operating cash flow indicate an unsustainable standalone operating model
- Cash balance of $19.94M versus $29.83M annual operating cash burn implies limited runway
Key Metrics to Watch
- Cash runway and burn rate trajectory; critical for assessing survival timeline
- Clinical trial progress and regulatory milestones for pipeline candidates
- Operating expense control and path to revenue generation or strategic alternatives
- Quarterly operating cash burn relative to cash and equivalents
- Any emergence of collaboration, licensing, or product revenue that validates growth quality
AN2 Therapeutics, Inc. (ANTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.87x current ratio provides a solid financial cushion.
ANTX Profit Margin, ROE & Profitability Analysis
ANTX vs Healthcare Sector: How AN2 Therapeutics, Inc. Compares
How AN2 Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AN2 Therapeutics, Inc. Stock Overvalued? ANTX Valuation Analysis 2026
Based on fundamental analysis, AN2 Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AN2 Therapeutics, Inc. Balance Sheet: ANTX Debt, Cash & Liquidity
ANTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AN2 Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
ANTX Revenue Growth, EPS Growth & YoY Performance
AN2 Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ANTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AN2 Therapeutics, Inc. (CIK: 0001880438)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANTX
What is the AI rating for ANTX?
AN2 Therapeutics, Inc. (ANTX) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANTX's key strengths?
Claude: Excellent liquidity position with current ratio of 6.87x and $19.9M cash reserves. No long-term debt burden with debt/equity ratio of 0.00x, reducing financial risk. ChatGPT: Strong short-term liquidity with a 6.87x current and quick ratio. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in ANTX?
Claude: Pre-revenue stage with zero commercial product income and N/A gross margins indicating no commercialization. Severe negative cash burn of -$29.8M annually with only ~8 months of cash runway at current burn rate. ChatGPT: No revenue base, making the company entirely reliant on external financing and pipeline execution. Large net loss and negative operating cash flow indicate an unsustainable standalone operating model.
What is ANTX's revenue and growth?
AN2 Therapeutics, Inc. reported revenue of N/A.
Does ANTX pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
Where can I find ANTX SEC filings?
Official SEC filings for AN2 Therapeutics, Inc. (CIK: 0001880438) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANTX's EPS?
AN2 Therapeutics, Inc. has a diluted EPS of $-1.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, AN2 Therapeutics, Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANTX stock overvalued or undervalued?
Valuation metrics for ANTX: ROE of -66.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANTX stock in 2026?
Our dual AI analysis gives AN2 Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANTX's free cash flow?
AN2 Therapeutics, Inc.'s operating cash flow is $-29.8M, with capital expenditures of N/A.
How does ANTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -66.3% (avg: 15%), current ratio 6.87 (avg: 2).